Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 248

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Open access
Tam, Constantine S., Allan, John N., Siddiqi, Tanya, Kipps, Thomas J., Jacobs, Ryan, Opat, Stephen, Barr, Paul M., Tedeschi, Alessandra, Trentin, Livio, Bannerji, Rajat, Jackson, Sharon, Kuss, Bryone J., Moreno, Carol, Szafer-Glusman, Edith, Russell, Kristin, Zhou, Cathy, Ninomoto, Joi, Dean, James P., Wierda, William G., Ghia, Paolo · 2022 · Blood

Abstract

CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. Patients received 3 cycles of ibrutinib lead-in then 12 cycles of ibrutinib plus venetoclax (oral ibrutinib [420 mg/d]; oral venetoclax [5-week ramp-up to 400 mg/d]). The primary endpoint was complete response (CR) rate. Hypothesis testing was performed for patients without del(17p) with prespecified analyses in all treated patients. Secondary endpoints included undetectable minimal residual disease (uMRD) rates, progression-free survival (PFS), overall survival (OS), and safety. Of the 159 patients enrolled and treated, 136 were without del(17p). The median time on study was 27.9 months, and 92% of patients completed all planned treatment. The primary endpoint was met, with a CR rate of 56% (95% confidence interval [CI], 48-64) in patients without del(17p), significantly higher than the prespecified 37% minimum rate (P < .0001). In the all-treated population, CR rate was 55% (95% CI, 48-63); best uMRD rates were 77% (peripheral blood [PB]) and 60% (bone marrow [BM]); 24-month PFS and OS rates were 95% and 98%, respectively. At baseline, 21% of patients were in the high tumor burden category for tumor lysis syndrome (TLS) risk; after ibrutinib lead-in, only 1% remained in this category. The most common grade ≥3 adverse events (AEs) were neutropenia (33%) and hypertension (6%). First-line ibrutinib plus venetoclax represents the first all-oral, once-daily, chemotherapy-free FD regimen for patients with CLL. FD ibrutinib plus venetoclax achieved deep, durable responses and promising PFS, including in patients with high-risk features.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2021014488

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 248

Metadata

Authors
Tam, C. S., Allan, J. N., Siddiqi, T., Kipps, T. J., Jacobs, R., Opat, S., Barr, P. M., Tedeschi, A., Trentin, L., Bannerji, R., Jackson, S., Kuss, B. J., Moreno, C., Szafer-Glusman, E., Russell, K., Zhou, C., Ninomoto, J., Dean, J. P., Wierda, W. G., & Ghia, P.
Venue
Blood
Published
2022-06-02
Volume
139
Issue
22
Pages
3278-3289
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4213453359
Cited by
248
References
1
FWCI
25.30
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. https://app.cochat.ai/papers/10.1182/blood.2021014488
The paper
Tam, C. S., Allan, J. N., Siddiqi, T., Kipps, T. J., Jacobs, R., Opat, S., Barr, P. M., Tedeschi, A., Trentin, L., Bannerji, R., Jackson, S., Kuss, B. J., Moreno, C., Szafer-Glusman, E., Russell, K., Zhou, C., Ninomoto, J., Dean, J. P., Wierda, W. G., & Ghia, P. (2022). Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. https://doi.org/10.1182/blood.2021014488

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.